Group 1 - The company, 加科思-B, has signed a capital increase agreement and a share transfer agreement with an industry partner, involving a total payment of RMB 2 billion for acquiring 80% of 加科瑞康 [1][2] - After the completion of the transaction, 加科思 will own 10% of 加科瑞康, 海松资本 will own 80%, and the industry partner will hold 10% [1] - 加科瑞康 focuses on the internal research and development of cardiovascular disease treatment drugs and holds relevant intellectual property for early-stage cardiovascular research and development projects [1] Group 2 - The company is committed to developing innovative oncology products and solutions to improve health outcomes [2] - The transaction aligns with the company's strategic focus on key oncology pipeline products targeting various critical cellular pathways, optimizing capital allocation, and enhancing organizational efficiency [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [2]
加科思-B(01167)：北京加科思拟透过增资协议及股权转让协议出售加科瑞康90%股权